Gland Pharma Q1 FY26 YoY PAT up by 50% to Rs. 216 Cr
Cenexi reports an EBITDA breakeven for the quarter
Cenexi reports an EBITDA breakeven for the quarter
Athena is also exploring the use of this technology for expanded carrier screening
The average baseline SALT score was 83.8, indicating about 16% scalp hair coverage
Vasograin Plus represents a major advancement in the treatment of migraine
EBITDA rose to Rs. 218.1 crore, a 14.8% year-on-year increase
The system, called GeneAgent, cross-checks its own initial predictions for accuracy against information from established, expert-curated databases
7-OH is a concentrated byproduct of the kratom plant and has shown potential for abuse by binding to opioid receptors
The facility includes advanced laboratories to monitor market trends, consumer needs, product innovation, and formulation improvements
Subscribe To Our Newsletter & Stay Updated